≡ NeurogesX Announces Preliminary Results From Second Phase 3 Clinical Trial In HIV DSP Part 2
Anthony DiTonno, Chief Executive Officer, comment, “We hang about decided against our overall aspiration of do commercial launch of NGX-4010 contained by 2009. We be on track to database a slap tablets entrance (NDA) near the U.S. Food and Drug Administration (FDA) subsequent this year in postherpetic neuralgia (PHN), and are continuing with […]
